News | September 08, 2008

September 9, 2008 - Lantheus Medical Imaging Inc. issued a statement assuring regulatory authorities, key customers and partners that they will continue to receive supply of molybdenum-99 (Mo-99), the parent isotope of Technetium-99m (Tc-99m) in their TechneLite generators, during the current global isotope shortage and will continue to fulfill preexisting standing orders and try to meet additional demands during this critical time.

Lantheus said it will continue to serve the needs of patients and the nuclear medicine community, and to mitigating the effect this shortage has on nuclear imaging studies and patient care.

On several past occurrences of Tc-99m generator supply issues, Lantheus faced similar challenges and was able to address supply demands. Lantheus said it is fully prepared for this current situation and has requested additional production of Mo-99 to ensure the company is once again well-positioned in the face of increased customer demand.

The company will continue to supply the medical isotope to the worldwide markets until complete resolution of these shortage issues.

For more information: www.radiopharm.com


Additional Content

News | FDA

March 18, 2026 — FluoGuide A/S, a biotech company maximizing surgical outcomes in oncology, has announced that the U.S ...

Time March 24, 2026
arrow
News | PET-CT

Feb. 27, 2026 — A new targeted PET/CT tracer can detect treatment response in rheumatoid arthritis patients in as little ...

Time February 26, 2026
arrow
News | PET Imaging

Jan. 26, 2026 — Nuclidium, a clinical-stage radiopharmaceutical company developing a proprietary copper-based ...

Time January 27, 2026
arrow
News | Prostate Cancer

Sept. 26, 2025 — A new fast and convenient approach to scintigraphy-based monitoring allows physicians to efficiently ...

Time October 03, 2025
arrow
News | Radiopharmaceuticals and Tracers

Sept. 20, 2025 — A promising new PET tracer can visualize a protein that is commonly overexpressed in triple-negative ...

Time September 18, 2025
arrow
Subscribe Now